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Background: In spite of the potential impact upon population health and expenditure, interventions promoting
medication adherence have been found to be of moderate effectiveness and cost effectiveness. Understanding the
relative influence of factors affecting patient medication adherence decisions and the characteristics of individuals
associated with variation in adherence will lead to a better understanding of how future interventions should be
designed and targeted. This study aims to explore medication-taking decisions that may underpin intentional
medication non-adherence behaviour amongst a community sample and the relative importance of medication
specific factors and patient background characteristics contributing to those decisions.
Methods: A discrete choice experiment conducted through a web-enabled online survey was used to estimate the
relative importance of eight medication factors (immediate and long-term medication harms and benefits, cost,
regimen, symptom severity, alcohol restrictions) on the preference to continue taking a medication. To reflect more
closely what usually occurs in practice, non-disease specific medication and health terms were used to mimic
decisions across multiple medications and conditions.161 general community participants, matching the national
Australian census data (age, gender) were recruited through an online panel provider (participation rate: 10%)
in 2010.
Results: Six of the eight factors (i.e. immediate and long-term medication harms and benefits, cost, and regimen)
had a significant influence on medication choice. Patient background characteristics did not improve the model.
Respondents with private health insurance appeared less sensitive to cost then those without private health
insurance. In general, health outcomes, framed as a side-effect, were found to have a greater influence over
adherence than outcomes framed as therapeutic benefits.
Conclusions: Medication-taking decisions are the subject of rational choices, influenced by the attributes of
treatments and potentially amenable to intervention through education, strategic pricing and the altering of dosing
characteristics. Understanding individual treatment preferences is thus an important step to improving adherence
support provision in practice. Re-framing future interventions and policies to support rational and informed
individual patient choices, is the way forward to realising the full potential health and economic benefits from the
efficacious use of medications.* Correspondence: thar7910@uni.sydney.edu.au
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In developed countries, it is estimated that 50% of patients
prescribed medications do not adhere to therapy [1]. Rates
of non-adherence are estimated to be greater still within
marginalised groups and in developing countries [1,2]. In
spite of the potential to impact upon population health
and expenditure [3], interventions to promote adherence
have been shown, at best, to be of moderate effectiveness
and cost effectiveness [4-6].
Recent evidence has indicated that a significant level
of non-adherence is intentional involving deliberate deci-
sions to adjust medication use [7-14]. Various factors have
been individually associated with such medication-taking
decisions including side effects, perceived drug effective-
ness, and cost. However, the lack of a gold standard meas-
ure and indeed a lack of consensus on the definition of
adherence have hindered any consistent and reliable set of
conclusions to be drawn from the literature. Despite the
recognition of the various factors that individually influ-
ence adherence, little is understood of their relative im-
portance, their potential interactions and the extent to
which individuals’ trade off one attribute of treatment for
another in their decision-making.
Discrete Choice Experiment (DCE) is a survey meth-
odology that can be used to elicit patient preferences to
determine the relative influence of factors on decision
making with regard to intentional medication adherence.
Developed initially in marketing research, and now con-
sidered state of the art, DCEs have been used increas-
ingly in health economics to elicit preferences for health
services [15-18]. Recently, there have been two DCE
studies that have explored and found a positive relation-
ship between the impact of patient preferences for medi-
cation effectiveness and side effects on likely adherence
in patients with bipolar disorder [19] and with diabetes
[20]. In both studies, the effect of broader factors affect-
ing adherence such as cost and treatment regimen were
not included.
One other limitation of the DCE studies that have
been conducted to date in this area is that they have
been disease or regimen-specific. However with the
possible exception of psychiatric conditions, there is
some evidence to suggest that is an overly narrow perspec-
tive [5]. In practice, patients are likely to balance factors
across multiple medications and across multiple condi-
tions [11,12,21]. This study aims to explore medication-
taking decisions that may underpin intentional medication
non-adherence behaviour amongst a community sample
and the relative importance of medication specific factors
and patient background characteristics contributing to
those decisions.
Methods
A cross-sectional web-enabled survey was used.Survey instrument
The survey used a discrete choice experiment (DCE) to
estimate the relative importance of medication factors
on one’s decision to continue with a medication. The
survey comprised three sections: the first contained
questions regarding current medication use and implicit
attitudes to medication using the Beliefs About Medica-
tion Questionnaire (BMQ) – General [22], the second,
the DCE (10 hypothetical choice tasks), and the third,
background information about the respondent.Instrument development
In a DCE, respondents are offered a series of hypothet-
ical pairwise alternatives (choice sets), and asked for
each, to nominate the preferred alternative. Each alter-
native is described by a set of factors with pre-specified
levels. The levels assigned to each alternative are varied
successively across all choice sets. For this study, a set of
factors covering four domains (i.e.: effect on current life,
effect on future life, medication access, and ease of
administration) were initially established through a sys-
tematic qualitative review of the qualitative and quantita-
tive (observational) medication-taking literature published
in English between 2000-May 2009 (Medline, Embase,
PsychInfo and Cinahl) involving adult patients across all
settings currently prescribed medications for chronic
non-communicable diseases, and more specifically for
cardiovascular disease (primary and secondary preven-
tion). Studies only involving children/adolescents were
excluded, as well as studies involving psychiatric, military
or institutionalised patients to avoid the potential influence
of psychosocial or institutional controls over adherence.
Furthermore, quantitative studies that used surrogate mea-
sures of adherence (e.g. blood pressure) were excluded.
The factors were further refined throughout survey pre-
testing [15], amongst pharmacists and members of the
general public to capture diverse educational, vocational,
and medication-experience backgrounds. Eight factors
considered most important through pre-testing and
used in the final survey are summarised in Additional
file 1. Additional file 1 also includes description of the
levels of each factor. As the study was to be conducted
within a general population with diverse medication
experiences, extensive descriptions of each factor were
presented in the survey preamble (see Figure 1). Fur-
thermore, considering the diverse diseases, symptoms,
medications and side effects possible, concepts of medi-
cation and health were described in non-disease spe-
cific terms.
The final survey included 10 choice sets. In each,
respondents were presented with hypothetical long-term
medication alternatives, ‘Medication A’ and ‘Medication
B’. Respondents were asked to imagine they were
Figure 1 Description of factors provided to respondents.
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they would more prefer to continue to keep taking.
On the basis of the exhaustive combination of factors
and levels listed in Additional file 1, a statistically effi-
cient design was generated using the choice experiment
design software Ngene Version 1.0 [23]. The design was
manually checked to ensure that each factor was
balanced across the choice sets. The final experimental
design consisted of 32 choice sets that were divided
into 4 survey versions. Two additional choice sets were
added to each survey version to check for consistency
(a repeated choice set) and internal validity (a choice set
with a dominated alternative according to a priori
expectations – see Additional file 1). Rather than test
for survey understanding, these tests are included to in-
vestigate whether responses are ‘rational’ according to
the axioms of preference-based consumer theory [24].
Thus, each survey version comprised 10 choice sets.
Each respondent was randomly assigned to one of four
survey versions. An example choice set is presented in
Figure 2. The survey was pilot tested (n = 18) to checkfor any problems with interpretation and face validity;
only minor changes to layout were made.
Participants
Based on the sample size calculations in Louviere et al
[25], using the survey design characteristic, participants
were recruited through Survey Sampling International,
Australia (SSI), an online panel provider (minimum
recommended sample size 48, without incorporating
participant taste variability). Respondents on the SSI
panel community are sourced non-probabilistically from
all areas of the internet including SSI global panels, so-
cial media, and websites; respondent duplication or
fraud is policed according to SSI policy. For this study,
English-reading, Australian, adult (>18 years of age)
panel members were invited to participate in the survey.
The final sampling quota was requested to be represen-
tative of the national census data in terms of age and
gender. Participants received entry into a competition
conducted by SSI for prizes of value up to $AU2000. For
participants completing the survey in less than 25
Figure 2 Example choice question in the discrete choice experiment. This figure is representative of one choice set. The levels of each factor
changes from one choice set to the next.
Laba et al. BMC Family Practice 2012, 13:61 Page 4 of 10
http://www.biomedcentral.com/1471-2296/13/61minutes, an opportunity to select a charity of which part
of the income generated by SSI is donated was also
given. An online participant information sheet was pro-
vided. Completion of the survey was considered as
inferred consent.Analyses
Considering the vast number of factors affecting adher-
ence across different types of medical conditions and
treatments [26], a panel mixed multinomial (random
parameters) logit (MMNL) model was used to analyse
the choice data. This is a common method for analysing
choice data in discrete choice experiments as it accounts
for the panel-like structure of the repeated choice task
and allows for a more general representation of variation
in preferences between individuals [15,25]. This is in
comparison to data segmentation via subgroup analyses,
which requires a priori selection of the correct segmen-
tation criteria and cut-offs that would account for statis-
tically significant sources of preference heterogeneity.
This study investigated changes in utility (U) (i.e. pre-
ference to continue with a medication) when a level of a
factor changes. A higher or more positive utility indi-
cates increased preference to continue with a medica-
tion. The model assumed that the relationship of
observed factor levels of each alternative and theircorresponding weights is linear and corresponds to the
following form:
U ¼ αþ β1  current side effect severityð Þ
þβ2  chance of future unwanted medicationeffectsð Þ
þ β3  symptom frequency while on medicationð Þ
þ β4  chance of early deathfrom illness while on medicationð Þ
þ β5  out of pocket monthly costð Þ
þ β6  symptomseverityð Þ þ β7  regimenð Þ
þ β8  alcohol restrictionsð Þ þ Eisj
ð1Þ
where U is the utility or preference and β(1–8) are the
associated parameter estimates or relative weights for
each factor. An alternative specific constant (α) was spe-
cified to capture left to right bias and to represent the
mean of the distribution of the unexplained effects. The
parameter estimates describe the magnitude of the utility
change and indicate the relative impact of a unit change
of a factor to the decision.
The choice model was estimated using NLOGIT Ver-
sion 4.0. All the β parameters were considered linear,
and initially treated as random with normal distribution
with the exception of cost, which was initially treated as
random with a constrained triangular distribution. Mod-
els were evaluated for goodness of fit using McFadden’s
pseudo R2 and Akaike’s information criterion (AIC). The




users (n = 111)
Medication
non-users (n = 50)
Age, median (range), y 59 (21–81) 44 (18–71)*
Gender (male), No. (%) 47 (42%) 25 (50%)
Education, No. (%)
≤ Year 12 or equivalent 52 (47%) 24 (48%)
> Year 12 or equivalent 59 (53%) 26 (52%)
Income (weekly $AU household,
before tax), No. (%)
< $650 47 (42%) 12 (24%)
≥ $650 46 (41%) 27 (54%)
Prefer not to answer 18 (16%) 11 (22%)
Health Care Concession Card
Holder (yes), No. (%)
72 (65%) 26 (52%)
Private Health Insurance (yes), No.
(%)
57 (51%) 20 (40%)
Number Household Dependents,
No. (%)
0 86 (77%) 32 (64%)
≥ 1 25 (23%) 18 (36%)
Ever Taken Prescribed Medications
(no), No. (%)
0 (0%) 6 (12%)*
Complementary/Natural Therapy
Use (yes), No. (%)
54 (49%) 23 (46%)
Beliefs about Medication –
general, mean (sd)
26.9 (5.8) 24.6 (5.4)*
Number of prescribed
medications, median (range)
3 (0–24) Not Applicable
* P<0.05 Medication users compared to non-users, χ2 test (proportions),
Mann–Whitney U test (non-parametric), independent sample t-test
(parametric).
Table 2 Current prescribed medication use
Current prescribed medication use Medication users (n = 111)
>6 months duration of use, (yes), No. (%) 106 (96%)
7-day non-adherence (yes), No. (%) 24 (22%)
12-month non-adherence, (yes), due to:
Cost No. (%) 8 (7%)
Side Effects, No. (%) 9 (8%)
Other, No. (%) 16 (14%)
12-month non-persistence (yes), due to:
Cost, No. (%) 12 (11%)
Side Effects, No. (%) 15 (14%)
Other, No. (%) 14 (13%)
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nificance of a model against each other and to test for
overall model significance compared to a model of the
average utility (i.e. using the choice shares observed
within the dataset). Final analyses were conducted using
1000 Halton or quasi-random draws from the random
parameters distribution, which accelerates the estimation
by a factor of 5–10 compared to simple pseudo-random
draws [27].
The effect of patient background characteristics on the
final model was investigated by forward stepwise
addition. Backwards elimination of significant covariates
was then performed. Additionally, it was hypothesised
that there may be a differential parameter associated
with the out-of-pocket cost factor. In Australia, the
government subsidises the cost of medicine for most
medical conditions through social health insurance
(Medicare), with a co-payment for each prescription paid
by consumers. People with a healthcare concession card
(HC) are entitled to government-subsidised medications
at a reduced co-payment rate. Private health insurance
(PHI) is an optional medical insurance that may provide
cover for the costs of medications that are not subsi-
dised by Medicare. The Australian government provides
income and age-related tax rebates and levies to increase
the uptake of PHI. A differential out-of-pocket cost fac-
tor was therefore investigated based on household in-
come level (INC), as well as healthcare concession card
(HC) or private health insurance (PHI) through the in-
corporation of cost-factor interaction terms.
From the final model, the predicted choice outcomes
for the sample as compared to the actual choice out-
comes as they exist within the data were calculated. The
relative importance of factors and their levels [17,28]
were investigated.
The University of Sydney Human Research Ethics
Committee approved this study (approval number 9-
2009/12074).
Results
Of the 1668 panel members initially invited to partici-
pate, 248 respondents began the survey, with 161
respondents (median age 57 years, 45% Male) complet-
ing the survey (participation rate 10% [29]). The partici-
pation rate indicates the efficiency of internet panels
that use non-probability based sampling methods for
participant selection and recruitment and in which re-
sponse rate has no real meaning [29]. As such, the par-
ticipation rate for this study reflects the expected rate
for this online panel provider.
A summary of the characteristics of the respondents
completing the survey is presented in Table 1 and
Table 2. Compared to the national Australian census,
the respondents were matched for age and gender, buthad a higher percentage of respondents completing Year
12 education or higher, with a weekly household in-
come < $AU650, holding PHI, and having 1 or more
household dependents (national census: 43%, 30%, 45%,
12.5% respectively) [30,31]. Just over half (61%) held a
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for health. Most respondents (96%) had experience with
taking prescribed medications. Of the respondents cur-
rently taking prescribed medications (69%), the majority
(96%) had been taking them chronically (>6 months).
Validity of responses
Of the 161 responses, 91% passed the monotonicity test
generally indicating “rational” interpretation of the fac-
tors as intended. Additionally, most of the parameter
estimates were significant (P < 0.05) and, with the excep-
tion of symptom severity, were in the expected direction.
For the repeated choice task, 77% of the respondents
passed and the kappa statistic was 0.48 representing
moderate agreement [32]. Two separate models exclud-
ing respondents who had failed each test were run to
investigate the effects on the model. For the monoton-
icity test, there was no difference in model parameter
estimates. For the completeness tests, the loss of statistical
power did not change the relative magnitude between par-
ameter estimates. As the deletion of such responses has
recently been cautioned against due in part to the short-
comings of the tests to truly detect irrationality and conse-
quent removal of potentially valid preference responses,
and considering that the existence of such preferences can
be seen to be consistent with random utility theory
[24,33], all responses were included in the final model.
DCE results
Additional file 2 shows the results of the DCE. The
results of the final model are displayed. The β coeffi-
cients represent the relative impact of a unit change of
each factor on the preference to continue with a medica-
tion. For instance, the negative sign of the side effect
severity parameter indicates that an increase in the side
effect severity of a medication decreases the relative pre-
ference for continuing with a medication.
Six of the eight factors were found to have a statisti-
cally significant effect on the decision to continue with a
medication. Specifically, those factors were those con-
cerning the harms or benefits of the medication as well
as cost and regimen. The presence of statistically signifi-
cant standard deviations associated with the mean par-
ameter estimates for factors concerning harms and
benefits suggest the existence of preference heterogen-
eity for these factors. The parameter estimates for the se-
verity of daily symptoms and the ability to drink alcohol
whilst taking the medication were not found to have a
statistically significant influence on respondent prefer-
ences for continuing a medication. The constant term (α)
was not significant indicating no general preference for
Medication ‘A’ over Medication ‘B’ when all factors and
levels were the same, and that factors not included in this
experiment had no significant effect on the results.No improvement in the model fit statistics (AIC or
McFadden’s pseudo R2) occurred with the addition of
respondent background characteristics displayed in Table 1
as covariates, including current use of prescribed medica-
tions. Additionally, the beta-parameters associated with
these covariates were not statistically significant. However,
the relative influence of cost on decisions appeared to be
influenced by private health insurance status, but not by
income or health care concession card status. Specifically,
respondents with private health insurance appeared to be
less sensitive to cost when deciding to continue with a
medication compared to those without private health
insurance (β: 0.004, P: 0.0534). As this effect was
approaching significance, two separate cost parameters
were therefore created for each private health insurance
group and incorporated into the model.
For respondents with private health insurance, the out
of pocket costs for a medication was not statistically sig-
nificant (P= 0.08). In contrast, for respondents without
private health insurance, an increase in the out of pocket
cost for a medication was found to decrease the prefer-
ence to continue with a medication (P < 0.001). The final
model, displayed in Additional file 2, was found to be sta-
tistically significant compared to a model assuming equal
choice shares at the α=0.05 level (χ2 = 291.1*, df =13).
This model represented an acceptable fit [27] and was
predicting 58% of actual choices made.
Inputting the parameter estimates from the final
model and levels of factors into the utility function
(Equation 1) provides information on how respondents
were willing to trade between levels of factors. For
instance, switching from a medication taken four times a
day to one taken once a day, results in an increase in
preference (U) to continue with a medication by 0.2811
if all other factor levels remain equal. However, respon-
dents would prefer to continue with the more complex
regimen if there was a 20% decrease in the risk of future
unwanted medication effects with the new medication
relative to the old medication.
The relative importance of the factors using the popu-
lation beta-estimates and incorporating the range of fac-
tor levels is displayed in Additional file 2. In general the
ability of the medication to reduce the risk of death was
most important, followed by current side effect severity
and risk of future side effects. The number of doses per
day was of least importance relative to the other signifi-
cant factors. Accounting for preference heterogeneity
around the factors for harms and benefits, using the
individual beta estimates to calculate relative importance
at the individual level revealed that 58% of respondents
considered factors concerning harms of greater import-
ance than benefits (Table 3). Furthermore, with respect
to side effects, current side effects were mostly consid-
ered as more important than the risk of future side
Table 3 Relative importance of medication harms and
benefitsa- individual level
Comparison Number of respondents
(%), (n = 161)
Harms (overall) > Benefits (overall)b 94 (58%)
Harms (immediate) > Harms (long-term)c 86 (53%)
Benefits (immediate) > Benefits (long-term)d 30 (19%)
a Using individual parameter estimates, the relative importance of factors for
medication harms and benefits was investigated using the coefficient range for
each factor. The coefficient range is the difference between the smallest
(negative) part worth utility and the largest part worth utility within factor levels.
b This represents the number of respondents with the sum of the coefficient
ranges for the factors “severity of current side effects” and “chance of future
unwanted medication effects” greater than the sum of the coefficient ranges
for the factors “frequency of symptoms while on the medication (current)” and
“chance of early death from the illness while on the medication (future)”.
c This represents the number of respondents with the coefficient range for the
factor “severity of current side effects” greater than the coefficient range for
the factor “chance of future unwanted medication effects”.
d This represents the number of respondents with the coefficient range for the
factor “symptom frequency while on medication (current)” greater than the
coefficient range for the factor “chance of early death from the illness while
on the medication (future)”.
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reduce the risk of death was considered more important
than reductions in symptom frequency.Discussion
To the best of our knowledge, this is the first study that,
within a community sample, has used a DCE to explore
the relative influence of factors on decisions to continue
with prescribed medications. Such decisions underscore
the concept of intentional medication adherence. The
results of this study show that respondents’ preferences
to persist with medications were, in order of importance,
influenced by long-term medication benefits, current se-
verity and future risk of medication side effects, reduced
out-of-pocket costs, short-term medication benefits, and
fewer doses per day. This study extends the present lit-
erature by characterising the complexity of medication-
taking decisions, and in particular, how these decisions
are arrived at through the deliberative processes of trad-
ing between multiple treatment factors.
Within this study, preferences to continue with the
hypothetical medications presented were found to be
independent of patient background characteristics previ-
ously found to have mixed effects on actual adherence
within the literature [26]. This finding suggests that
medication-taking decisions are driven by one’s valuation
of the underlying attributes of a medication [11] and
that, consistent with previous research [13], intentional
medication adherence may be a behaviour that is not
strongly associated with patient characteristics. This
underscores the potential importance of eliciting a
patients’ valuation of medication factors as a means to
understanding medication-taking decisions.Consistent with the literature, this study has found
that the number of daily medication doses was signifi-
cant in influencing one’s preference to continue with a
medication [26]. However, in contrast to a recent quali-
tative study [21], the medication-taking decisions in this
study were not dominated by one medication factor. By
inputting parameter estimates and factor levels, it was
shown that reducing the dosing frequency alone might
not increase a patient’s decision to continue with a
medication if other significant factors, such as the side
effect profile of the medication, are perceived as overly
compromised. This finding may help to explain why
reductions in dosage frequency, as a stand-alone adher-
ence enhancing intervention, have resulted in only mod-
est improvements in overall adherence [5].
Medication cost is generally accepted internationally as
a major determinant of adherence [1,34,35]. Within the
DCE, when considered alongside other factors, out-of
pocket drug cost was found to have a significant influence
on one’s preference to continue with a medication. This
effect was irrespective of respondent’s income level or if
the actual co-payment currently paid for medications was
lower. However, out of pocket cost appeared to have a
stronger influence on medication choice for those without
private health insurance, which is not surprising given that
insurance status in Australia may provide supplementary
coverage for drugs not covered through the government
subsidised social health insurance, Medicare.
The amount, type, and format of information to
present to patients, particularly regarding medication
harms and benefits, and the effect it has on medication
acceptance and behaviour is often debated [36-41].
Alongside other factors, respondents in this study gener-
ally took into account both medication harms and bene-
fits into their medication-taking decisions. On the
whole, these were considered of higher relative import-
ance than regimen, which is typically a focus for improv-
ing adherence. Consistent with the literature [11,42],
medication harms were collectively considered of greater
importance than medication benefits. The higher relative
weight of medication harms and benefits in this study
confirms the importance of this information upon
medication-taking decisions [36,41] and suggests a need
to reflect these preferences in future policies aimed at
improving the safe and efficacious use of prescribed
medications within the community.
In contrast to what might be expected, the severity of
disease symptoms did not have a significant influence on
the decision to continue with a medication. This does
not imply that symptom severity is not important to the
decisions made, but on balance was neither having a
positive or negative influence [15,26,31]. Nonetheless,
respondents conflating symptom severity with medica-
tion side-effects may have influenced this result.
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have in attributing symptoms to the disease or the medi-
cation [11], and this current result may have been influ-
enced by these two factors being described on the same
scale. However, a previous DCE of patient preferences
for asthma medication has also found a non-significant
influence from the combined factor of symptom severity
and frequency on medication choice unless reduced to a
minimal level [43]. The present study suggests that
adverse health outcomes that are believed to be iatro-
genic weigh more heavily on patient medication-taking
decisions than health outcomes that are associated with
the natural course of illness.
The relative importance of immediate versus future
health outcomes differed substantially when framed as
either medication harms as opposed to therapeutic bene-
fits. Specifically, more respondents placed a greater value
on current harms (i.e.: side effect severity) than future
harms (i.e. 10-year risk of future side effects) reflecting
an implicit discounting of harms. Such reasoning is con-
sistent with conventional economic logic and reflects at
an intuitive level the prominence placed on medication
side effects on individuals’ day to day experience with
medications [11]. However when considering therapeutic
benefits the findings are less intuitive. More respondents
considered future benefits (i.e. 10-year reduced risk of
death) more important than current benefits (i.e.
reduced frequency of symptoms), which would suggest a
negative rate of discounting for therapeutic benefits.
This apparently irrational response could reflect the dif-
ficulties respondents may have had discussed above in
disentangling possible therapeutic outcomes from
changes in health caused by the natural course of illness.
The results of this study must be viewed in light of its
limitations. First, the use of an online panel provider has
precluded description of non-responders and potential re-
sponder bias. In particular, the individuals’ motivational
traits, recently demonstrated to predict internet panel and
survey participation, may limit the generalisability from
web-panels based on strictly demographics-based weight-
ing schemes [44]. Additionally, although an MMNL model
was used to account for the unobservable preference het-
erogeneity in the sampled population, other background
medical information, particularly the number, type and
experience with chronic conditions and medications, in-
cluding psychiatric conditions, as well as cultural/ethnicity
information were not accounted for. Furthermore, the
sample was not matched to the national Australian census
on other potentially important variables such as education
and income. It is also acknowledged that this study has
been conducted within one health system. These factors
may limit the generalisability of the findings. However, this
study was not attempting to quantify preferences or gener-
alise such numbers, but rather, investigate the relationshipbetween factors relevant to a variety of medications that
may be used across many different conditions and health
care settings. The lack of difference in patient preferences
between different health care settings found in another
study [20], particularly considering cost was not the pri-
mary driver within our study, supports the international
relevance of this study. Nonetheless, although the use of
an efficient design facilitates smaller sample sizes [45], lar-
ger, international, studies across different healthcare set-
tings and amongst subsets of chronically ill patients and
medication users, that are statistically powered for a priori
subgroup analyses, are warranted.
Second, respondents were given generic descriptions
of disease and treatment. Whilst it could be argued that
there are significant challenges in responding to this type
of abstraction, it was felt that this was necessary to
mimic decisions across multiple diseases and medica-
tions and thus address the main study question. Encour-
agingly, a meta-analysis of non-psychiatric adherence
research over 50 years and across many different condi-
tions including HIV, cardiovascular disease, and neuro-
logical disorders, has found that non-adherence was not
statistically significantly related to the type or severity of
disease [46].
Finally, while discrete choice methods are widely used
in health economics, an inherent limitation is that
respondents are evaluating hypothetical medications;
that is what respondents declare they will do may be
quite different to what they would actually do when they
experience the consequences of a choice [27]. Arguably,
forcing respondents to choose between medications may
also be contrary to actual behaviour [25], particularly
considering the over-riding influence of a prescribers’
recommendation upon patient preventive treatment
decisions suggested by Gale et al [47]. To minimise such
potential differences, measures were taken to design the
hypothetical tasks to be as realistic as possible [15,27],
for instance by centring levels of cost about current
medication co-payments and describing severity of
medication harms and benefits in terms of their effect
on health status. Encouragingly, a recent study that
applied the discrete choice framework to analyse actual
adherence data from a HIV clinical trial dataset has also
found side effects, regimen and medication effectiveness
to influence adherence [48]. As this study has measured
intended medication-taking decisions, future studies
incorporating actual adherence data [27,48] are needed to
determine the relationship between intended and actual
behaviour.
Conclusions
Improving adherence to medications, particularly for
chronic conditions, has been highlighted as a priority
area for policy development [49] and for improving
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http://www.biomedcentral.com/1471-2296/13/61clinical practice [50]. To do so, it must be acknowledged
that, outside of the consultation room, patients ultim-
ately have and do exercise the power to follow, modify
or reject prescribed treatment [11]. That is, a part of this
health behaviour is the subject of rational choices, influ-
enced by the attributes of treatments and potentially
amenable to intervention through education, strategic
pricing and the altering of dosing characteristics. Under-
standing individual treatment preferences is thus an im-
portant step to improving adherence support provision
in practice. Considering the modest effect of current
adherence-enhancing interventions to date [5,6], re-
framing future interventions and policies to acknowledge
and support rational and informed individual patient
decisions that may underpin intentional medication
adherence behaviour, rather than simply addressing
‘aberrant’ and ‘irrational’ behaviour, may be the way for-
ward to realising the full potential health and economic
benefits from the efficacious use of medications.
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